Enfermos de Cáncer y Familiares Denuncian a Sanidad por su « Pasividad » con el Tabaco .

Para estos afectados, según señaló ayer el citado despacho, es «absolutamente intolerable» que el Estado «mire hacia otro lado» en un asunto de tanta repercusión social y sanitaria «dando primacía al efecto recaudatorio del tabaco por encima de la salud de los españoles, máxime cuando es por todos conocidos que alrededor del 80% del precio del tabaco corresponde a impuestos».

...

Un nuevo biomarcador para el diagnóstico precoz del Alzheimer .

El nuevo biomarcador –una disminución de los niveles de ADN mitocondrial (mtDNA) circulante– identificado por el grupo de Trullas tiene la gran ventaja de poder ser medido de forma precisa utilizando ensayos de Reacción en Cadena de la Polimerasa (PCR).

La alteración en la concentración de mtDNA aparece hasta 10 años antes de los síntomas de la enfermedad y también precede a los cambios de Ab1-42 en el líquido cefalorraquídeo, que era la primera alteración en el alzhéimer conocida hasta el momento.

...

Yondelis , Segun Oncologos del Royal Marsden Hospital de Londres , para el Tratamiento de Sarcomas es Activo y Seguro .

2013 Aug 12.
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J, Judson I.

Source The Royal Marsden Hospital, Sarcoma Unit , Fulham Road, London, SW3 6JJ , UK .


Trabectedin gained the approval by the European Medicines Agency (EMA) in 2007 for the treatment of patients affected by soft-tissue sarcomas (STS). Its safety and activity profiles have been assessed in many clinical trials as well as in standard clinical practice for > 10 years.

Areas covered: This article extensively reviews the most common and specific adverse events associated with trabectedin. Moreover, we compare these toxicity data with other drugs active in STS such as doxorubicin and ifosfamide. Also, we provide a comprehensive view of the special mechanism of action of this drug and its clinical applications. Additionally, we discuss the current role of trabectedin in the treatment of STS and give a future perspective with the review of ongoing clinical trials and potential new indications.

Expert opinion: Trabectedin is, in general, a well-tolerated drug with a favorable toxicity profile. The majority of its side effects are mild and easily manageable. Specific adverse events such as liver toxicity and rhabdomyolysis do not usually have a significant clinical impact.

Overall, trabectedin is a safe and active treatment option in STS.

Aplidin . Fase III Myeloma in Combination with Dexamethasone versus Dexamethasone alone in Patients with Relapsed / Refractory Multiple Myeloma ... al Día .

*.- 24 de octubre de 2008: La Food and Drug Administration (FDA) Aceptó la Propuesta de PharmaMar, del Grupo Zeltia, sobre el proceso de producción de Aplidin® .




*.- En Junio de 2010 inicia dicha Fase III ADMIRE con 250 Pacientes en 65 Hospitales repartidos entre EEUU , Australia , Austria , Belgica , Republica Checa , Francia , Alemania , Grecia , Irlanda , Italia , Holanda , Portugal , Reino Unido y España .

*.- Aplidin para esta indicación posee el Status de Orphan drug , tanto en EEUU como en EU , lo cual le otorga varias ventajas ... una de ellas es la exclusividad de mercado en caso de aprobación de 7 años en EEUU y 10 años en EU ...

*.- Diciembre 2012 : Alcanza el objetivo inicial para la tasa de respuesta y el IDMC recomienda que se complete el ensayo de la Fase 3 (ADMYRE) .

*.- A Fecha de hoy son ya 6 los Hospitales que han comunicado que el Ensayo a " Terminated " .

*.- Estimated Study Completion Date: June 2014 .


*.- En Relación :
Plitidepsin (Aplidin) is intended to be used in combination with dexamethasone as third line therapy for the treatment of patients with multiple myeloma (MM). If licensed, it would provide an additional treatment option for this patient group. Plitidepsin is a cyclic depsipeptide identified from the Mediterranean marine tunicate, Aplidium albicans.

MM develops from plasma cells in the bone marrow and is the 17th most common cancer in the UK, accounting for around 1.5% of all new cases. Median survival for MM is approximately 3 to 5 years. In 2011, 2,330 deaths from MM were registered in England and Wales, 86% of which were in people aged 65 and over. The latest prevalence data suggests that at the end of 2006 there were 12,465 patients alive up to 10 years after their diagnosis. In 2009, 4,270 people were diagnosed with MM (ICD-10: C90) in England and Wales, giving a crude incidence rate of 8 per 100,000 population.

Treatment regimens for MM will be patient specific and dependent on performance status, eligibility for high dose chemotherapy with stem cell transplantation support, and frailty. There is no standard treatment option for patients who fail both bortezomib- and lenalidomide-based regimens. Plitidepsin is currently in a phase III clinical trial comparing its effect on MM against dexamethasone. This trial is expected to report in June 2014.